Targeted Immunotherapy in Oncology Market Research Report 2021: Development of New Targeted Immunotherapies, Particularly Those that Deliver Therapeutic DNA and Proteins

Dublin, January 17 2022–(BUSINESS WIRE)–The report “Targeted Immunotherapy in Oncology” has been added to Show.

This research service investigates the technologies driving the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins.

The top three growth opportunities focus on improved gene delivery systems for greater precision, support for these systems through new biotechnology platforms, and the affordability of precision medicine/targeted immunotherapies through modular, decentralized manufacturing systems.

In terms of technology, nonviral gene delivery and DNA delivery offer important safety advantages, particularly from immunogenicity and carcinogenesis. Not using viral vectors also makes the regulatory pathway and biomanufacturing process more accessible since no additional precautions are required; This, in fact, makes the price even lower.

The study explores the advantages and limitations of viral and nonviral gene delivery systems for targeted immunotherapies. The safety of administration without immunity remains the most relevant advantage. Liposomes have no reproductive risks and are less immune to viruses.

The versatility of gene delivery systems is widely measured in terms of transfection efficiency, accuracy in cancer immunotherapy, and ability to cross the membrane barrier. For a remarkable innovation in biotechnology platforms, the research highlights gene addition as a new approach that uses a delivery system to introduce new genes directly into cells. The functional gene can be added either ex vivo (ex vivo) or in vivo (in vivo) and can be used in cancer immunotherapy through CAR T-cell technology.

Gene delivery strategies rely on a comprehensive set of clinically approved technologies, including electroporation, liposomes, nanoparticles, and nonviral and viral delivery modalities. Electroporation is best suited for the efficient delivery of blood cells and immune cells ex vivo. It is best indicated for lipid nanoparticles (LNP) for in vivo delivery to the liver and possibly other organs. Adenocarcinoma-associated vectors are typically used for in vivo delivery to the eye and central nervous system (CNS).

For the optimal manufacturing process, ceDNA vectors show a linear and continuous structure, which can be used to insert the transgene into a gene safe harbor (GSH) in the genome. For gene delivery, cell-targeted lipid nanoparticles (ctLNP) designed to avoid immune system activation at the initial dose can be used, while capsule-free approaches can be used to facilitate manufacturing.

This research summarizes a notable number of successful companies in the field of targeted immunotherapy. A competitive analysis of the top three innovators, based on their IP activity and focus on patent innovation, is included. Funding and investment are also covered, including leading deals and investors focused on technologies that enable targeted immunotherapies.

Main points discussed:

1. The most significant innovation in biotechnology platforms has focused on targeted immunotherapies

2. Emerging technologies in direct gene and nucleic acid delivery systems

3. Outstanding Companies That Succeed in Targeted Immunotherapy

4. Industrial landscape and industry patent filing trends

5. Major deals and investors focused on developing new technologies for targeted immunotherapies

6. Growth Opportunities in Targeted Immunotherapy Area

7. Best practices for risk management while developing new technologies that enhance targeted immunotherapies

Main topics covered:

1.0 Strategic imperatives

1.1 Why is it getting harder to grow? Strategic imperative: factors that create pressures on growth

1.2 Strategic determinism

1.3 Impact of the three most important strategic imperatives on targeted immunotherapies

1.4 About the growth pipeline engine

1.5 Growth opportunities fuel the growth pipeline

1.6 Research Methodology

2.0 Analysis of Growth Opportunities

2.1 The growing success of gene and cell therapies, gene-editing technologies, and new gene delivery platforms

2.2 Customized Targeted Immunotherapy Framework

2.3 Leading immunotherapy technology platforms

2.4 Appropriate immunotherapy modalities for the purpose

2.5 Regulatory environment

2.6 search context

2.7 Research Scope

3.0 The need for targeted immunotherapy in oncology

3.1 Biotechnology platforms for cancer immunotherapy

3.2 Drivers and Accelerators

3.3 Challenges and limitations

4.0 Technology assessment for targeted immunotherapies in oncology

4.1 Classification of targeted therapies

4.2 Technologies that enable targeted immunotherapies

4.3 Gene editing tools and stem cell reprogramming

4.4 Requirements for next-generation targeted immunotherapy

4.5 Delivery of viral and nonviral vectors in gene and cell therapies

4.6 Practical opportunity plays for biopolymers and biotherapies in gene therapy

4.7 Innovation System and Collaboration Centers

4.8 Key Partnerships and Alliances in Gene Delivery

4.9 Companies Focusing on Viral and Nonviral Gene Delivery Systems in Targeted Immunotherapy

4.10 New synergies in gene delivery systems drive the success of targeted immunotherapy

4.11 Companies focusing on gene editing and stem cell reprogramming techniques

4.12 Companies Focusing on Medicinal Chemistry and Platform Chemistry Technologies

5.0 Pipeline analysis of targeted immunotherapies in oncology

5.1 Key technologies to drive pipelines and software for a biotech company

5.2 Case for clinical validation of non-viral gene delivery systems

5.3 Competitive landscape

5.4 Modern Treatment Pipeline Dashboard: Inhibrx, Inc.

5.5 The most up-to-date therapeutic pipeline dashboard: BioNTech SE

5.6 Modern Therapeutic Pipeline Dashboard: Adaptimmune Therapeutics llc.

5.7 The most up-to-date therapeutic pipeline dashboard: Asher Bio

5.8 Modern Therapeutic Pipeline Dashboard: Gritstone bio

5.9 Modern Therapeutic Pipeline Dashboard: Jounce Therapeutics, Inc.

6.0 Stakeholders benefit from genomics tools for research and development

6.1 In vivo gene transfer, Homology Pharmaceuticals, United States

6.2 Next-generation AAV capsids, Abeona Therapeutics, US

6.3 CRISPR Gene Editing, Modified Medicine, United States

6.4 AAV, Zinc Finger Exonucleases, Sangamo Therapy, US

6.5 Electroporation, Nonviral (LNP), Viral (AAV), Beam Therapeutics, US

6.6 Custom AAV Vectors, 4D Molecular Therapy, United States

6.7 T-cell Immunotherapy – Microfluidic Spiral Shedding, Indy Laboratories, US

6.8 Micro-editing Gene Editing Technology, Poseida Therapeutics, United States

6.9 Lentiviral gene delivery, Avrobio, United States

7.0 companies to work

7.1 Gene Therapy for Rare Diseases, Ultragenyx Drugs, United States

7.2 AAV Gene Delivery Technology, Spark Therapeutics (Roche), United States

7.3 Gene replacement and gene knockdown, Voyager Therapeutics, US

7.4 AAV Gene Delivery Technology, AGTC, United States

7.5 LV Gene Delivery and Vehicle T Cell Technology, Bluebird Bio, US

7.6 DNA nanoparticles, Copernicus Therapeutics, United States

8.0 Financing and Investment Analysis

8.1 Funding and Investment Evaluation of Targeted Oncology Immunotherapy

8.2 Leading R&D investments in targeted immunotherapy platforms

8.3 Key deals in targeted immunotherapy platforms

8.4 Major Investors in Targeted Immunotherapy Platforms

8.5 Investor Movements in Targeted Immunotherapy Platforms

8.6 Government funding in targeted immunotherapy platforms

8.7 Factors of key nodes in targeted immunotherapy platforms

8.8 Aiding upstream treatments in targeted immunotherapy platforms

8.9 Evaluation of Venture Capital Financing in Targeted Immunotherapy

8.10 Venture capital financing deals in Targeted Immunotherapy

9.0 Patent portfolio analysis of key stakeholders

9.1 Competitive intelligence, radiotherapy

9.2 Competitive Intelligence, BlueBird Bio

9.3 Competitive Intelligence, Vital Generation

10.0 A world of growth opportunities

10.1 Growth Opportunity 1: Gene Delivery and Nucleic Acid Delivery for Rare and Genetic Diseases

10.2 Growth Opportunity 2: Innovative Biotechnology Platforms for Precision Immunotherapy

10.3 Growth Opportunity 3: Decentralized Modular Manufacturing for Affordable Targeted Genetic Immunotherapy

10.4 Best practices for risk management in targeted immunotherapy

11.0 Next Steps

For more information on this report, visit

View the source version on

Laura Wood, Senior Director of Press
[email protected]
For EST office hours, call 1-917-300-0470
For US/Canada Toll Free Call 1-800-526-8630
For GMT office hours, call +353-1-416-8900

Leave a Comment